Description
NCI-H929 is a human B lymphocyte, suspension cell line derived from the bone marrow of a patient with advanced multiple myeloma (62-year-old female). This cell line’s surface antigen profile is: PCA-1 +, CD38+, CD138+, CD19+, CD45+, CD56+, CD40+, CD54+, CD20-, CD10-, CD34-, CD14-, CD3-, HLA-DR -, EBNA-.
NCI-H929 is extensively used for studying multiple myeloma other B-cell malignancies. The cell line is used in the development and testing of immunotherapies, including monoclonal antibodies and CAR-T cell therapies, aimed at the surface antigens.
This RFP / human NCI-H929 cell line expresses the codon-optimized monomer RFP fluorescent marker. RFP was expressed under the enhanced EF1a Promoter. Cell line carries the Puromycin resistance.
The following expression cassette was integrated into the cell line’s genome:
Each cell showed RFP fluorescent signal. see a sample image below:
Sold at: 1 vial x (2 x 106 cells)/vial, see details in Product Manual.
Cat# SC099-R
